Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 2
2011 1
2012 3
2013 4
2015 2
2016 4
2017 1
2018 6
2019 2
2020 4
2021 5
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
Butler LM, Mah CY, Machiels J, Vincent AD, Irani S, Mutuku SM, Spotbeen X, Bagadi M, Waltregny D, Moldovan M, Dehairs J, Vanderhoydonc F, Bloch K, Das R, Stahl J, Kench JG, Gevaert T, Derua R, Waelkens E, Nassar ZD, Selth LA, Trim PJ, Snel MF, Lynn DJ, Tilley WD, Horvath LG, Centenera MM, Swinnen JV. Butler LM, et al. Among authors: centenera mm. Cancer Res. 2021 Oct 1;81(19):4981-4993. doi: 10.1158/0008-5472.CAN-20-3863. Epub 2021 Aug 6. Cancer Res. 2021. PMID: 34362796
ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, Dehairs J, Burvenich IJG, Zadra G, Chetta PM, Bango C, Evergren E, Ryan NK, Gillis JL, Mah CY, Tieu T, Hanson AR, Carelli R, Bloch K, Panagopoulos V, Waelkens E, Derua R, Williams ED, Evdokiou A, Cifuentes-Rius A, Voelcker NH, Mills IG, Tilley WD, Scott AM, Loda M, Selth LA, Swinnen JV, Butler LM. Centenera MM, et al. Cancer Res. 2021 Apr 1;81(7):1704-1718. doi: 10.1158/0008-5472.CAN-20-2511. Epub 2021 Feb 5. Cancer Res. 2021. PMID: 33547161
Maximizing the Therapeutic Potential of HSP90 Inhibitors.
Butler LM, Ferraldeschi R, Armstrong HK, Centenera MM, Workman P. Butler LM, et al. Among authors: centenera mm. Mol Cancer Res. 2015 Nov;13(11):1445-51. doi: 10.1158/1541-7786.MCR-15-0234. Epub 2015 Jul 28. Mol Cancer Res. 2015. PMID: 26219697 Free PMC article. Review.
Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
Hinneh JA, Gillis JL, Mah CY, Irani S, Shrestha RK, Ryan NK, Atsushi E, Nassar ZD, Lynn DJ, Selth LA, Kato M, Centenera MM, Butler LM. Hinneh JA, et al. Among authors: centenera mm. Br J Cancer. 2023 Oct;129(8):1350-1361. doi: 10.1038/s41416-023-02406-8. Epub 2023 Sep 6. Br J Cancer. 2023. PMID: 37673961 Free PMC article.
Hsp90: still a viable target in prostate cancer.
Centenera MM, Fitzpatrick AK, Tilley WD, Butler LM. Centenera MM, et al. Biochim Biophys Acta. 2013 Apr;1835(2):211-8. doi: 10.1016/j.bbcan.2012.12.005. Epub 2012 Dec 31. Biochim Biophys Acta. 2013. PMID: 23287571 Review.
Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.
Nassar ZD, Mah CY, Dehairs J, Burvenich IJ, Irani S, Centenera MM, Helm M, Shrestha RK, Moldovan M, Don AS, Holst J, Scott AM, Horvath LG, Lynn DJ, Selth LA, Hoy AJ, Swinnen JV, Butler LM. Nassar ZD, et al. Among authors: centenera mm. Elife. 2020 Jul 20;9:e54166. doi: 10.7554/eLife.54166. Elife. 2020. PMID: 32686647 Free PMC article.
38 results